In stable coronary disease, hs-cTnI is associated with the incidence of heart failure or death, but this relationship depends on other variables.
that its use is increasing in clinical practice, it is important to understand the clinical significance of the positivity of high-sensitivity cardiac troponin (hs-cTn) in patients with cardiovascular disease.
As conventional troponin, hs-cTn is used for the diagnosis and prognosis of acute coronary syndromes [3, 4] . However, in recent years it has been suggested that hs-cTn could have prognostic value in several disorders, such as heart failure (HF) [5] [6] [7] , pulmonary embolism and pulmonary hypertension [8] , in patients with cardiovascular risk factors [9, 10] , in subjects of middle or advanced age [11] [12] [13] , and in stable coronary artery disease (SCAD) [14, 15] . However, the possible role of hs-cTn in SCAD as a prognostic biomarker is not clear. In addition, we are still far from understanding what causes the elevation of this biomarker in conditions other than acute coronary syndrome. Although hs-cTn is theoretically released only by the myocardium during necrosis, it has been proven that it also rises in other diseases in which it is additionally a death marker [16] . In this work, we studied the prognostic value of hs-cTnI in 705 patients with SCAD.
Materials and Methods
The research protocol complied with the Helsinki Declaration and was approved by the ethics committees of the participant hospitals. All patients signed informed consent documents. The BACS (Biomarkers in Acute Coronary Syndrome) and BAMI (Biomarkers in Acute Myocardial Infarction) studies included patients admitted at the Fundación Jiménez Díaz, Fuenlabrada, Móstoles and Alcorcón hospitals in Madrid with either non-ST elevation acute coronary syndrome (NSTEACS) or ST-elevation myocardial infarction (STEMI). The inclusion criteria have been previously defined [17] . The exclusion criteria were age over 85 years, the coexistence of other significant cardiac disorders, such as cardiomyopathies, present pericardial disease or valve disease (cases with left ventricular hypertrophy secondary to hypertension, nonsevere valve regurgitation without anatomic abnormalities, and degenerative aortic stenosis with a mean gradient lower than 25 mm Hg were allowed to enter the study), the coexistence of any illness or toxic habits that could limit patient survival, impossibility to perform revascularization when indicated, and subjects in whom follow-up was not possible. In order to avoid variability of findings due to an excessive heterogeneity in the intervals between the acute event and blood extraction, the investigators agreed to exclude patients that were not clinically stable at day 6 of the index event.
In addition to plasma withdrawal at discharge, a second plasma sample was extracted between 6 and 12 months later, on an outpatient basis. This paper reports data from the clinical and analytic findings obtained at this second plasma extraction, relating them to subsequent follow-up.
Between July 2006 and April 2010, 1,898 patients were discharged from the hospitals of the study with a diagnosis of NSTEACS or STEMI. Eight hundred and thirty-eight patients were included in the study. The remaining patients were not included due to the following: age over 85 years (17.3%), presence of disorders or toxic habits limiting survival (29.0%), impossibility to perform cardiac revascularization (14.5%), coexistence of another significant cardiac disorder (6.8%), impossibility to perform follow-up (12.0%), clinical instability beyond the 6th day at the index event (9.1%), refusal to participate in the study (2.0%), and impossibility of the investigators to include them because of holiday periods (9.3%). Of the 838 patients included, 7 died before the second visit, and 710 had available adequate plasma samples at that time. This visit took place between January 2007 and February 2011. The final follow-up visits took place in May 2012.
Study Design
At baseline, a complete set of clinical variables of the patients was recorded and 12-hour fasting venous blood samples were withdrawn and collected in EDTA. Blood samples were centrifuged at 2,500 g for 10 min and plasma was stored at -80 ° C. Patients were seen every year at their hospital. At the end of follow-up (maximum 4.6 years) the medical records were reviewed and patient status was confirmed by telephone contact.
The secondary outcomes were: (1) recurrence of acute ischemic events, such as NSTEACS, STEMI, stroke or transient ischemic attack, and (2) incidence of HF or death. The primary outcome was the composite of the secondary end points.
NSTEACS was defined as rest angina lasting for more than 20 min in the previous 24 h, or new-onset class III-IV angina, along with transient ST depression or T wave inversion in the electrocardiogram considered diagnostic by the attending cardiologist and/ or conventional troponin elevation. STEMI was defined as symptoms compatible with angina lasting for more than 20 min and ST elevation in 2 adjacent leads in the electrocardiogram without response to nitroglycerin, and troponin elevation. A past myocardial infarction was diagnosed when new pathological Q waves were present in the electrocardiogram along with a new myocardial scar identified either by echocardiography or nuclear magnetic resonance imaging in the same myocardial region. Stroke was defined as the rapid onset of a persistent neurological deficit attributable to a focal vascular cause lasting for more than 24 h, or of less duration if imaging studies reported the presence of new ischemic lesions. A transient ischemic attack was defined as a transient stroke with signs and symptoms resolving before 24 h, without new ischemic lesions in imaging studies. Events were adjudicated by at least 2 investigators of the study, along with a neurologist for cerebrovascular events.
Analytical Studies
Laboratory analyses were carried out at the Clinical Biochemistry Laboratory at the IIS-Fundación Jiménez Díaz by investigators who were unaware of the clinical data. Hs-cTnI was assessed by direct chemiluminescence (ADVIA Centaur; Siemens, Berlin, Germany), and high-sensitivity C-reactive protein was determined by latex-enhanced immunoturbidimetry (ADVIA 2400 Chemistry System; Siemens). Lipids, glucose and creatinine determinations were carried out by standard methods (ADVIA 2400 Chemistry System).
Statistical Analysis
Quantitative data that followed a normal distribution are presented as the mean ± standard deviation and compared using the Cox's proportional hazards model was performed with forward, stepwise selection to assess the variables associated with the primary and the secondary outcomes. Variables with p < 0.05 were entered into the model, and those with p > 0.10 were removed. In model 1, the risk of events was estimated according solely to the values of hs-cTnI. In model 2, risk was adjusted for age and sex. Finally, in model 3, the following clinical, analytical and treatment variables were added: diabetes, smoking status, hypertension, body mass index, lipid levels; previous history of peripheral artery disease, cerebrovascular events, atrial fibrillation; ejection fraction <40%, glomerular filtration rate (GFR) assessed by the chronic kidney disease epidemiology collaboration method (CKD-EPI); highsensitivity C-reactive protein; therapy with aspirin, clopidogrel, statins, acenocumarol, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, nitrates/nitroglycerin and diuretics; the type of the most recent acute coronary event, the number of diseased vessels and existence of complete revascularization at that event. Kaplan-Meier curves and log-rank test were used to compare time to outcome according to a multimarker score. A two-sided p < 0.05 was considered significant. Analyses were performed with SPSS 19.0 (SPSS Inc., New York, N.Y., USA).
Results
Five patients were lost to follow-up, so the study population was finally made up of 705 patients. Hs-cTnI was >0 ng/ml in 62.1% of cases, with median and maximal values of 0.008 (0.003-0.017) and 3.446 ng/ml, respectively. Cases with hs-cTnI >0 were older, had a lower GFR, a more frequent history of hypertension, atrial fibrillation, left ventricular ejection fraction <40% and therapy with angiotensin-converting enzyme inhibitors, diuretics and acenocumarol than those with hs-cTnI = 0, with no significant differences in the other variables at univariate analysis ( table 1 ) . The follow-up period was 2.2 ± 0.99 years.
Fifty-three patients developed acute ischemic events: there were 4 STEMI, 22 NSTEACS, 17 cases of unstable angina, 8 strokes and 10 transient ischemic attacks. Four patients suffered 2 events and 2 patients experienced 3 events.
Thirty-three patients developed the secondary outcome of HF or death. There were 16 episodes of HF and 23 deaths, with 6 patients suffering both events. Nine deaths were due to cardiovascular causes and 4 to malignancies. Infection, renal failure, bowel ischemia, gastrointestinal bleeding and pancreatitis each accounted for 1 death. Five deaths were of unknown etiology. Of the 9 cardiovascular deaths, 4 were due to HF, 3 were sudden deaths, 1 was due to NSTEACS with HF and 1 was due to NSTEACS alone. Ultimately, 78 patients developed the primary outcome.
Hs-cTnI was more frequently positive in patients who developed the primary outcome (79.5 vs. 60.0%; p < 0.001) and HF or death (90.6 vs. 60.8%; p < 0.001). Nevertheless, there was not a significant association with the occurrence of acute ischemic events (73.6 vs. 61.2%; p = 0.079).
The concentration of hs-cTnI was higher in patients who developed the primary outcome [0.010 (0.001-0.025) vs. 0.002 (0.000-0.009) ng/ml; p < 0.001] and the composite end point of death and HF [0.023 (0.007-0.047) vs. 0.002 (0.000-0.010) ng/ml; p < 0.001] than in those who remained stable. Here again, these differences were not significant for the development of acute ischemic events (0.056 ± 0.247 vs. 0.154 ± 3.566 ng/ml; p = 0.841).
Kaplan-Meier curves showed that patients with hscTnI >0 were more likely to develop the primary outcome ( fig. 1 a) and HF or death ( fig. 1 b) , but not acute ischemic events ( fig. 1 c) . By Cox's regression, in the univariate analysis ( table 2 , model 1), hs-cTnI >0 was associated with a higher risk of developing the primary outcome. However, when controlling for age (model 2) and for the other variables described previously (model 3), the statistical significance was lost. The results were similar when we analyzed the risk of HF or death during the follow-up ( table 3 , models 1-3) and did not vary if these two events were analyzed separately (not shown). Finally, hs-cTnI >0 was not associated with the recurrence of acute ischemic events in the univariate analysis (not shown). By logistic regression analysis, from all the variables described in table 1 that were significantly different in the groups with hs-cTnI >0 and hs-cTnI = 0, only age, left ventricular ejection fraction <40%, treatment with acenocumarol and GFR were significantly associated with the hs-cTnI >0 group ( table 4 ) .
Discussion
Coronary artery disease is highly prevalent. In a recent cross-sectional study in Spain, 4.9% of the population older than 40 years had this diagnosis [18] . There are several clinical risk scores to predict outcomes in patients with acute coronary syndromes, such as the TIMI risk score [19] and the GRACE score [20] . In addition to clinical variables, troponin plasma levels are included in these scores. However, with the exception of lipid levels, no risk score or biomarker has been unanimously accepted for risk stratification of patients with SCAD. Nevertheless, in the SCAD guidelines of the European Society of Cardiology [21] , risk stratification is considered to be an important part of the management of these patients because it identifies those at higher risk who could potentially benefit from a more aggressive therapeutic strategy.
Though the use of cardiac troponins is well established in the management of patients with an acute coronary syndrome, it has also been described that plasma troponin levels are increased in 0.7% of the general population between the ages of 30 and 65 years [22] . Moreover, only 53% of patients who have troponin elevation on admission receive a main diagnosis of acute coronary syndrome [16] . The other medical conditions of these patients include arrhythmia, sepsis, pulmonary and neurological diseases, and renal failure. Death rates were higher in this group of patients, suggesting a relationship between elevated troponin levels and an increased noncoronary mortality [16] .
The availability of hs-cTn assays allows for a better understanding of the relationship of this biomarker with other diseases. The prevalence of detectable hs-cTnT is 25% in the population aged between 30 and 65 years [11] , 66.5% in the those aged 54-74 years [13] , and 66.2% in 6 adults >65 years [12] . Concentrations of hs-cTn were higher in men, African Americans and individuals with chronic kidney disease [23] . Hs-cTnT levels have been associated mostly with aging, the presence of traditional cardiovascular risk factors, low estimated GFR, high levels of inflammatory biomarkers [11, 24] , left ventricular hypertrophy, left ventricular systolic dysfunction, a history of HF, elevated concentrations of brain-type natriuretic peptide, the presence of atrial fibrillation [24, 25] , coronary calcification, and soft/mixed plaques in the CT coronary angiography [26] . According to this, increased levels of hs-cTnT have been found in 78% of ambulatory patients with hypertension and no history of HF, and in 45% of women with diabetes mellitus [9, 10] . In our study, we also found a relationship between hs-cTn and a worse clinical profile because patients with detectable concentrations of hs-cTnI had a higher prevalence of hypertension, atrial fibrillation and left ventricular ejection fraction <40%, more frequent use of diuretics and a lower estimated GFR than those without detectable hs-cTn.
Regarding the prognostic value of hs-cTn, several studies have described associations between increased levels of this biomarker and future risk of HF or death. This connection has been observed in the general population without a history of previous cardiac disease [2, 23] , in patients with SCAD [14, 15, [27] [28] [29] and HF [5] [6] [7] , and even in patients with pulmonary embolism or pulmonary hypertension [8] . However, there is no consensus on the power of hs-cTn to predict the development of acute ischemic events. Some studies have found this relationship to exist, although with less predictive power than for mortality, or appearing in the context of composite outcomes including mortality [13, 24, 27] . Other investigations have shown no statistically significant relationship [28, 29] . Similar findings were observed in our study: at univariate analysis, hs-cTn was associated with the outcome of death, HF or acute ischemic events. However, only the outcome of death or HF was associated with high hs-cTn when a separate analysis was performed as hs-cTn did not predict the isolated risk of acute ischemic events.
The higher sensitivity of hs-cTn comes at the expense of specificity, and this must always be taken into account when interpreting the results in a particular patient. Elevated troponin concentrations are observed in noncardiac diseases, such as stroke, sepsis, adult respiratory distress syndrome, and even after strenuous exercise [30] . The etiology of these minor elevations in patients who do not have an acute coronary syndrome is being investigated because the release, degradation and elimination of this biomarker have not been completely elucidated. Several theories have been suggested for the different conditions, such as increasing oxidative stress and the effect of inflammatory cytokines in HF, decreased clearance in chronic kidney diseases, increased cardiomyocyte apoptosis in the set of increased ventricular load, or coronary microembolisms in patients with nonobstructive coronary disease [8, 31, 32] .
It seems clear that moderate elevations of hs-cTn in conditions other than acute coronary syndrome are associated with comorbidities and any degree of underlying heart disease that causes silent myocardial injury. In our study, the predictive value of hs-cTnI is clearly influenced by these factors (age, sex, low left ventricular ejection fraction, concurrence of atrial fibrillation or chronic kidney disease). Previous investigations have shown an independent relationship between the elevation of the hs-cTn and the risk of events at follow-up [27, 28] . Nevertheless, these findings resulted from clinical trials, where patient selection is influenced by the aims of the trial. Moreover, in these trials, patients were less frequently treated with β-blockers, statins and drugs acting on the renin-angiotensin system than they are now [15, 27, 28] . Moreover, in some of these studies, patients with left ventricular ejection fraction <40% were excluded [15, 28] . In contrast, our study included patients with low left ventricular ejection fraction, and the treatment they received was in accordance with the recently published guidelines on the management of SCAD [21] . Therefore, the clinical usefulness of this high-sensitive biomarker to assess risk in these patients is controversial. Our conclusions are in agreement with the European Society of Cardiology guidelines on the management of SCAD, which state that although there is some prognostic value associated with the amount of troponin, this value is not sufficient enough to recommend systematic measurement in out-of-hospital patients with SCAD [21] .
The limitations of our study include the exclusion of patients with clinical instability in the first days after the index event, as these patients would probably have had a worse prognosis. Nevertheless, only 9% of cases were excluded for this reason.
Conclusions
In patients with SCAD, high levels of hs-cTnI are associated with an increased incidence of HF or death. Nevertheless, this association does not have an independent prognostic value and is explained by age and other clinical variables.
